61 results about "Immunohistochemistry technique" patented technology

The invention belongs to the biotechnology field, relates to application of PSMD4 protein, and in particular relates to application of the PSMD4 protein in preparation of a liver cancer prognostic evaluation kit. The invention adopts an immunohistochemistry technology, a microscope photograph technology and computer image processing software to test the relative transcript level of PSMD4 protein of tumor tissues relative to the tumors and determine the correlation between the relative transcript level of PSMD4 protein and the prognosis of hepatocellular carcinoma patients after operation by a manner of combining the postoperative follow-up information. The PSMD4 protein can be used for preparing a protein molecular marker for judging prognosis of the liver cancer patients, and has important instruction significance to postoperative monitor and sequential therapy of the hepatocellular carcinoma patients.

The invention relates to an in vitro method of predicting the therapeutic effect of interferon treatment on a patient with hepatitis C, which belongs to the in vitro diagnostic reagent category of the biological medicine and is a substantive improvement based on a patent being applied for at present. The interferon treatment is effective only for 50 percent of patients with hepatitis C. The clinical operation is short of a method of predicting the therapeutic effect before the treatment of hepatitis C. According to the positioning and analysis of the expression of the ISG15 or MxA protein in the liver tissue through the immunohistochemical technique before the treatment of patients with hepatitis C, the distributions of ISG15 or MxA are different in the liver tissues of the patients for whom the interferon treatment is effective and the patients for whom the interferon treatment is not effective: the expression of the genes in the liver cells indicates that the interferon treatment is not effective for the patients; and the expression of the genes in the macrophage cells indicates that the interferon treatment is effective for the patients. The method is used to predict the therapeutic effects of the interferon treatment on 31 patients with hepatitis C, and the rate of accuracy reaches 100 percent. The invention can predict whether the patient with hepatitis C is sensitive to the interferon treatment before the interferon treatment, thereby optimizing the patient management.

The method of the invention pertains to determining the signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance.

The invention relates to the technical field of immunohistochemistry, in particular to a fully automatic immunohistochemical system. The fully automatic immunohistochemical system includes a workbench, a sample loading table, a refrigerating component, a repairing component, an incubating component, a slide moving mechanism and a sample loading mechanism. The refrigerating component is arranged onthe workbench; and the refrigerating component includes a plurality of reagent bottles for storing reagents and a refrigerating unit for refrigerating the reagent bottles. A slide moving arm of the slide moving mechanism is arranged to grasp, rotate and transfer a slide module, and a sample loading arm is configured to load samples to different slide modules; and the cooperation of the slide moving arm and the sample loading arm can reduce human operations to a greater extent, so that the process of immunohistochemistry is more automated; and therefore, the machine throughput can be greatly increased. In addition, the refrigerating component is arranged on the workbench to achieve low-temperature storage of the reagents, and the reagents do not need to be taken repeatedly; therefore, theexperimental efficiency can be greatly improved. Through the fully automatic immunohistochemical system, the experimental throughput can be greatly increased, and the automated immunohistochemical experiment process can be more optimized.

The invention discloses the application of NFI transcription factors in esophageal squamous cell carcinoma, and particularly relates to the application of a transcription factor NFIB in the diagnosisof esophageal squamous cell carcinoma and the application of a transcription factor NFIA in evaluating the differentiation degree, TNM staging and prognosis of esophageal squamous cell carcinoma. Thelevel of the NFI transcription factors of esophageal squamous cell carcinoma is detected and analyzed by the immunohistochemical technique, it is found that patients with high expression of NFIA havea low tumor differentiation degree, a high TNM stage and poor prognosis, and high expression of NFIB corresponds to a low esophageal squamous cell carcinoma tissue differentiation degree, in this way,a new way is provided for the diagnosis and prognosis judgment of esophageal squamous cell carcinoma, and a reference is provided for clinicians to analyze the condition of patients with esophageal squamous cell carcinoma.

The invention relates to the technical field of immunohistochemistry, and especially relates to a wheel disc type immunohistochemical instrument. The wheel disc type immunohistochemical instrument comprises a workbench, a wheel disc transferring mechanism, a constant-temperature and constant-humidity box, a reagent groove assembly and a liquid adding mechanism, and the wheel disc transferring mechanism comprises a support arranged in the workbench, a wheel disc assembly rotationally arranged on the support and a plurality of supporting plate assemblies used for bearing slide modules. The wheeldisc transferring mechanism is placed in the constant-temperature and constant-humidity box, and all the slide modules can be subjected to liquid adding through the liquid adding opening, so that inthe periodic transfer process of the supporting plate assembly, liquid adding can be carried out on all the slide modules at the same time (the liquid adding action can be carried out for multiple times in multiple rotating periods, and reagents added each time can be different), and all the slide modules can be incubated. Moreover, the wheel disc transferring mechanism is adopted, so that the space occupied by the upper table top of the workbench can be reduced, and the treatment flux can be greatly improved on the premise of not increasing the size of the whole machine.

The invention provides a preparation method of artificial cutaneous melanoma tissues, including the culture of keratinocytes and melanoma cells of human skin as well as the preparation of biological matrix material. The keratinocytes and the melanoma cells of human skin are respectively inoculated on the biological matrix material in sequence, and by the adoption of a method combining culture under liquid and air-liquid level incubation, a certain culture medium is used under the conditions of 5 percent of CO2 and asepsis at 37 DEG C to culture and construct the cutaneous melanoma tissues. Methods of histology and immunohistochemistry technology are adopted for the observation of growth situation of the malignant cutaneous melanoma tissues. The melanoma tissues closer to the microenvironment of human skin are constructed by the preparation method and the observation by the histology method shows the obvious invasive growth of the melanoma tissues and the formation of obvious tumor metastases or tumor groups on the surface of HDED and in the lumen of the dermal accessory organ, thus meeting the distribution characteristics of the malignant melanoma tissues infiltrated in the dermis of human skin and reflecting that markers of the melanoma tissues show a positive reaction.

The invention relates to the field of biotechnology, in particular to an immunohistochemical technique based pathology assistant analysis method which comprises the following steps: acquiring a communication channel connected with a processing platform through a client; uploading pathology digital images so as to obtain a cell sample interval in the pathology digital images; setting a parameter set, and searching cells matching the parameter set in the cell sample interval as target cells; counting the amounts of positive cells and negative cells in the target cells according to staining colors of the target cells respectively; obtaining a ratio of the positive cells to the target cells, and outputting the ratio to the client; evaluating the accuracy of the ratio through the client by a user, and then supplying accuracy feedback to the processing platform; and regulating the parameter set. The technical scheme of the invention has the beneficial effects that the immunohistochemical technique based pathology assistant analysis method can assist a doctor to carry out pathology analysis based on an immunohistochemical technique, also has a feedback optimization mechanism and can improve the accuracy of diagnosis while lowering the labor cost of immunohistochemical diagnosis.

The invention discloses an immunohistochemical glass slide with an internal reference, which comprises a label mark zone, a to-be-tested sample paster zone and an internal reference mark zone, whereinthe internal reference mark zone is fixed with a cellular immunity chip containing at least three positive expression internal references and a negative expression internal reference; the at least three positive expression internal references comprise cell strains capable of stably expressing that the corresponding antigen intensities of target antibodies are weak positive staining, intermediatepositive staining and strong positive staining; the negative expression internal reference is the cell strain for not stably expressing corresponding antigens of the target antibodies. The immunohistochemical glass slide can correct objective operation error, intragroup experimental error and subjective defect of interpretation, and others existed in the existing immunohistochemical technique, andalso can discriminate the difference of the dyeing intensity, and can perform the quality control on the full process of the experimental detection and result report; thus the correctness and accuracy of the immunohistochemical experimental detection are guaranteed. The invention further provides a preparation method and an application of the immunohistochemical glass slide with the internal reference.

The invention belongs to the biotech field, relates to an application of an Shp2 protein, and concretely relates to an application of the Shp2 protein in preparation of a liver cancer prognosis evaluation kit. The relative Shp2 protein expression level of a tumor tissue to a tissue adjacent to the tumor is determined through utilizing an immunohistochemical technology, microscope shooting and computer image processing software, and postoperative follow-up information is combined to determine that the relative Shp2 protein expression level is related with the hepatocellular carcinoma patient prognosis after the operation, so the Shp2 protein can be used for preparing a protein molecule maker for determining the liver cancer patient, and is of great guiding significance to the postoperative monitoring and sequential treatment of hepatocellular carcinoma patients.

The invention relates to the technical field of medical biological detection and provides novel uses of WDR1, NMI and LIN28 proteins, particularly an application in preparation of a kit for assessingbrain glioblastoma prognosis. The invention further provides a kit and detection method performing brain glioblastoma prognosis assessing through quantitative detection of the WDR1, NMI and LIN28 proteins by adopting an immunohistochemical method. Expression levels of the WDR1, NMI and LIN28 proteins in brain glioblastoma tissues are measured by utilizing an immunohistochemical technique and system scoring, and it is determined that the expression levels of the WDR1, NMI and LIN28 proteins are related with prognosis of patients with brain glioblastoma after operations by combination with postoperative follow-up observation information. The combination of the WDR1, NMI and LIN28 proteins can be used for preparing a protein molecular marker for determining prognosis of patients with brain glioblastoma, and is of great directive significance for brain glioblastoma molecular subtyping, postoperative monitoring of patients and sequential therapy.

The invention relates to the technical field of biology, in particular to a pathology aided analysis method based on an immunohistochemical technique. The method can comprise a preset step that a pathological section treated through the immunohistochemical technique is scanned through a pathology scanner to obtain a pathology digital image, and further can comprise the steps that 1, the pathology digital image is input to obtain a cell sample interval; 2, a parameter set is set, and cells conforming to the parameter set are sought in the cell sample interval to serve as target cells; 3, the number of positive cells and negative cells in the target cells with two kinds of classification of the positive cells and the negative cells are counted according to dyed colors of the target cells; 4, a proportion value of the positive cells in the target cells is obtained according to the number of the positive cells and the negative cells, and the proportion value is output. The method has the advantages that a doctor can be assisted in conducting pathology diagnosis on the basis of the immunohistochemical technique, and the labor cost of immunohistochemical diagnosis is lowered.

The invention relates to application of cyclin protein G1. Relative expression quantity of the cyclin protein G1 between tumor tissues and tissue adjacent to tumor is determined by utilizing an immunohistochemistry technology, picture taking by a microscope and computer image processing software, correlation between the relative expression quantity of the cyclin protein G1 and prognosis of postoperative patient with hepatocellular carcinoma is determined by combining postoperative follow-up visit information, the cyclin protein G1 can be applied to preparation of a protein molecule maker for judging the prognosis of the patient with liver cancer and has importance directive significance for postoperative monitoring and sequential treatment for patients with hepatocellular carcinoma.

The invention belongs to the technical field of biomedicine, and particularly relates to the application of a molecular target in the prognosis prediction and treatment of esophageal squamous cell carcinoma. The molecular target is a long-chain non-coded RNA AGPG. The expression level of an AGPG gene in esophageal squamous cell carcinoma tissues is detected through RT-PCR, RNA scope in-situ hybridization, in-situ hybridization, a chip or a high-throughput sequencing platform. The expression level of a target protein PFKFB3 corresponding to the AGPG gene in the esophageal squamous cell carcinoma tissues is detected through immunoblot and an immunohistochemical technology. A biologically active drug is successfully developed, the biologically active drug comprises an inhibitor of the long-chain non-coded RNA AGPG and an inhibitor PFK15 of a PFKFB3 protein, and the biologically active drug can be effectively used for the prognosis prediction and treatment of the esophageal squamous cell carcinoma. A novel molecular target is provided for the prognosis prediction and treatment of the esophageal squamous cell carcinoma by a researching outcome, and a novel treatment strategy is providedfor the clinical treatment of the esophageal squamous cell carcinoma.

The invention discloses application of CHKA proteins in preparing a kit for prognostic evaluation of liver cancer. The expression amount of the CHKA proteins in the tumor tissue is determined by means of an immunohistochemical technique, microscope photographs and computer image processing software. The method for determining the expression amount of the CHKA can be used for judging the prognosis effect of the postoperative liver cancer patient, and provides important guidance for the postoperative monitoring and the sequential treatment of liver cancer patients. Moreover, the invention further discloses a kit for the prognostic evaluation of liver cancer and the method.

The invention discloses a cytobiology method for predicting the height of an excellent ice-snow athlete. An immunohistochemical technology and a flow cytometry are mainly used for conducting qualitative and quantitive detection and comparing an expression level of BMP2, BMP7 and BMP9 in bone morphogenetic protein (bone morphogenetic protein, BMP) in osteoblast of the excellent ice-snow athlete with the expression level of BMP2, BMP7 and BMP9 in the BMP in osteoblast of an ordinary person. A result shows that the expression quantity of the BMP2, the BMP7 and the BMP9 in the osteoblast of the excellent ice-snow athlete is higher than the expression quantity of the BMP2, the BMP7 and the BMP9 in the osteoblast of the ordinary person. The result indicates that a relatively higher expression quantity of the BMP2, the BMP7 and the BMP9 in the osteoblast of people is a reference standard of an optimal height. The cytobiology method for predicting the height of the excellent ice-snow athlete lays a solid theoretical and technical foundation for establishing a scientific system for early prediction and evaluation of potency of the ice-snow athlete, talent selection and talent education, and therefore theoretical and technical difficulty of one-time talent selection can be overcome.

The invention provides a multiple immunohistochemical analysis kit for liver cancer, and a using method and application thereof, and relates to the technical field of multiple immunohistochemistry. The multiple immunohistochemical analysis kit limits that monoclonal antibody groups comprise a first monoclonal antibody group and a second monoclonal antibody group; the first monoclonal antibody group comprises a PanCK monoclonal antibody, a PDL1 monoclonal antibody, a CD8 monoclonal antibody, a CD66B monoclonal antibody and a CD163 monoclonal antibody; the second monoclonal antibody group comprises a PanCK monoclonal antibody, a PDL1 monoclonal antibody, a CD8 monoclonal antibody, a PD1 monoclonal antibody and a CD68 monoclonal antibody. According to the multiple immunohistochemical analysiskit provided by the invention, the paraffin sections of the human liver tissue in vitro are used as samples for detecting, and thus the effectiveness of the immune checkpoint inhibitor acting on theliver cancer is predicted.

The invention relates to a kit and a detection method for detecting the CA199 expression of peripheral blood circulating tumor cells of a pancreatic cancer patient, and belongs to the technical fieldof molecular biology. The Kit comprises 45mL of diluent, 1mL of decolorizing liquid, 0.5mL of a staining solution A, 1mL of a staining solution dyeing B, 100[mu]L of a goat anti-CA199 primary antibody, 100[mu]L of rabbit anti-goat IgG / HRP, 100[mu]L of 0.1% Triton X-100, 100[mu]L of 0.3% H2O2, 15ml of a reagent A, 50ml of a reagent B, and 60ml of a 6*PBS buffer solution. According to the detectionmethod, the CTCs in peripheral blood of a patient suffering from advanced or recurrent pancreatic cancer and incapable of obtaining a tissue specimen are separated by using a membrane filtration device, and the CA199 expression condition of the CTCs is further detected by using an immunohistochemical technology.

The invention discloses a method for detecting E-Cadherin expression of colorectal cancer patient through peripheral blood circulating tumor cells. Specifically, a kit (45 mL of diluent, 1mL of decolorizing liquid, 0.5 mL of a staining solution A, 1 mL of a staining solution B, 100 [mu] L of a rabbit anti-human E-cad antibody, 100 [mu] L of goat anti-rabbit IgG / HRP, 100 [mu] L of 0.1% Triton X-100, 100 [mu] L of 0.3% H2O2, a reagent A, a reagent B, and 60 mL of a 6 * PBS buffer solution). The cancer period and recurrence condition of the patient are determined by collecting peripheral blood, pretreating the peripheral blood, enriching CTCs in the peripheral blood, dyeing and finally detecting the expression condition of genes by using an immunohistochemical technology.

The invention discloses a method for establishing a benign prostatic hyperplasia (BPH) canine model with epithelial-mesenchymal transition (EMT) characteristics, and belongs to the field of animal models and medical evaluation. The BPH canine model refers to a spontaneous BPH canine model and an induced BPH canine model. According to the method, an induced BPH model established in 10 days after estrogen / androgen in a ratio of 1: 100 is given to adult Beagle dogs is adopted, and the induced BPH model has a change trend consistent with that of a spontaneous BPH model in the aspects of prostate index, hormone level, proportion change of epithelium and mesenchyme (similar characteristics to human prostatic hyperplasia) and pathological histological examination, so that the success of the modelis confirmed. Furthermore, marker proteins corresponding to epithelium and mesenchyme are detected by adopting an immunohistochemical technology, and EMT is preliminarily found to be a hyperplasia inducement of fibrosis of interstitial parts of two BPH models. By utilizing the method disclosed by the invention, a stable spontaneous BPH canine model with EMT characteristics and an induced BPH canine model can be established, and the method can be used for screening medicines for treating benign prostatic hyperplasia and evaluating functions of foods or health-care products for improving benignprostatic hyperplasia, and has important application value.

The invention relates to the field of biomedicine, in particular to a method and a reagent kit for detecting expression quantities of TROP2 (trophoblastic cell surface antigen 2) proteins. The method includes staining normal tissues and to-be-detected sample tissues by the aid of immunohistochemical technologies and detecting the staining concentration and the staining ranges; acquiring staining concentration fractions according to the staining concentration and acquiring staining range fractions according to the staining ranges; acquiring staining indexes SI according to the staining concentration fractions and the staining range fractions; acquiring the expression quantities of the TROP 2 proteins according to the staining indexes SI. The method and the reagent kit have the advantages that the expression quantities of the TROP2 proteins can be scientifically detected by the aid of the method, high expression of the TROP2 proteins in NMIBC (non-muscle invasive bladder cancer) is discovered, and accordingly the TROP2 proteins are independent prognostic factors for NMIBC.

The invention relates to a kit and a detection method for detecting PD-L1 expression of peripheral blood circulating tumor cells of a pancreatic cancer patient, and belongs to the technical field of molecular biology. The kit comprises 45mL of a diluent, 1mL of decolorizing liquid, 0.5 mL of staining solution A, 1mL of dyeing liquid B, 100 [mu]L of an anti-human PD-L1 primary antibody, 100 [mu]L of goat anti-human IgG / HRP, 100 [mu]L of 0.1% Triton X-100, 100 [mu]L of 0.3% H2O2, 15 ml of a reagent A, 50 ml of a reagent B, and 60 mL of a 6*PBS buffer solution. CTCs in peripheral blood of advanced or recurrent pancreatic cancer patients who cannot obtain tissue specimens are obtained through separation by utilizing a membrane filtration device, and the PD-L1 expression condition of the CTCs is further detected by utilizing an immunohistochemical technology.

The invention provides a kit for detecting PD-L1 gene mutation of peripheral blood circulating tumor cells of a prostate cancer patient and a detection method. The kit comprises a diluent, a destaining , a staining solution A, a staining solution B, an anti-human PD-L1 primary antibody, an enzyme-labeled goat anti-human secondary antibody, 0.1% of Triton X-100, 0.3% of H2O2 and a reagent A. The detection method comprises the following steps: separating and acquiring peripheral blood circulating tumor cells (CTC) by using a membrane filtration device, and detecting the PD-L1 expression condition of the peripheral blood CTCs by using an immunohistochemical technology. By utilizing the detection method provided by the invention, the PD-L1 expression condition of a patient with advanced or recurrent hepatocellular carcinoma can be detected without acquiring a tissue specimen through needle biopsy, and real-time dynamic detection can be realized by utilizing a minimally invasive technology;by adopting the separation device and the diluent, the circulating tumor cells are well separated, the interference of blood cells is avoided, the false positive result caused by the edge effect possibly generated in the dyeing process is avoided, the stability is good, the cell loss is reduced, and the detection accuracy is improved.